Looking at current myelofibrosis treatments, momelotinib passed phase 3 trials and is only offering symptomatic relief. There is nothing disease modifying on the market at all for this cancer, and considering the phase 3 for a drug offering symptomatic relief only required 195 patients, I would assume any phase 2b/phase 3 for SNTs drug would be placed to conduct a much smaller trial.
Also, the treatment was only for 24 weeks with the sole primary endpoint being total symptom score. The FDA may add in another endpoint like spleen volume.
The point im trying to make is, any future development of SNTs drug will be a relatively small trial with not so difficult to meet endpoints typically seen in cancer drug development.
Another major consideration for SNT is how they plan to fund it. This is why the SP over the next year or so is critical. Doing a cap raise at low prices will destroy shareholder value, as it would be quite a substantial raise to fund a phase 2b/phase 3. Otherwise, they may look for a commercial transaction to help fund it.
Add to My Watchlist
What is My Watchlist?
